Buparlisib (BKM120)

For research use only.

Catalog No.S2247 Synonyms: NVP-BKM120

212 publications

Buparlisib (BKM120) Chemical Structure

CAS No. 944396-07-0

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.

Selleck's Buparlisib (BKM120) has been cited by 212 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.
Targets
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
Vps34 [1]
(Cell-free assay)
52 nM 116 nM 166 nM 262 nM 2.4 μM
In vitro

BKM120 is not sensitive to Class III and Class IV PI3K's or PI4K. NVP-BKM120 shows great antiproliferation activity to PI3K deregulated cell lines including A2780, U87MG, MCF7 and DU145 with GI50 of 0.1-0.7 nM. [1] BKM120 induces multiple myeloma cells (ARP1, ARK, MM.1S, MM1.R and U266) apoptosis, which results in increased G1-phase cells and decreased S-phase cells. BKM120 induced CD138+ primary MM cell apoptosis and has significant lower cytotoxicity toward CD138− stromal cells. BKM120 exposure could cause upregulation of BimS and downregulation of XIAP. [2] BKM120 demonstrates antiproliferative activity in human gastric cancer cell lines by decreasing mTOR downstream signaling. BKM120 could increase either p-ERK or p-STAT3 in KRAS mutant gastric cancer cells. Combination with STAT3 blockade, BKM120 shows a synergism in cells harboring mutated KRAS by inducing apoptosis, but not in KRAS wild-type cells. [3] A recent study shows that BKM120 shows differential forms of cell death on the basis of p53 status of the cells with p53 wild-type cells undergoing apoptotic cell death and p53 mutant/deleted cells having a mitotic catastrophe cell death. BKM120 mediates mitotic catastrophe mainly through Aurora B kinase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
glioma cell lines M1;UNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjuN2pEPzKq MYXJR|UxRTFvMt88US=> NFn6SZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC2OVA5OCd-MkKwOlUxQDB:L3G+
U87 M12xSWFxd3C2b4Ppd{BCe3OjeR?= MmSyNu69VQ>? M4fsclczcA>? M3rXNYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiYX7kJINt\WG4ZXSgVGFTWCCjbnSgZ4F{eGG|ZT2z M{DCbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{ME[1NFgxLz5{MkC2OVA5ODxxYU6=
SNU-601 Mmr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHXO|Jp MoPNSG1UVw>? NWK4e3Q4UUN3ME2wMlgyPsLzMD6wOlPPxE1? NILNWVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1PVgyPCd-MkKxOVk5OTR:L3G+
SNU-1 M3n0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLtW4NuPzKq M2jEcWROW09? NGf2VYRKSzVyPUGuNFgzyrFyLkCyPO69VQ>? NX7BN5VFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOVk5OTRpPkKyNVU6QDF2PD;hQi=>
SNU-668 NGHLXnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW[3Nog> NUnJXVd4TE2VTx?= MXzJR|UxRTFwNUe5xtExNjB5NN88US=> NYXzeohZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOVk5OTRpPkKyNVU6QDF2PD;hQi=>
AGS NWPsPJlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV73PJcyPzKq MnnqSG1UVw>? NXn5SXF3UUN3ME2xMlcyPMLzMD6xNVfPxE1? MnT3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNUm4NVQoRjJ{MUW5PFE1RC:jPh?=
SNU-216 NV7IbIlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWG4TllpPzKq NI\4fZhFVVOR NITVeYZKSzVyPUKuOlkzyrFyLkC4Nu69VQ>? M3uzU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUW5PFE1Lz5{MkG1PVgyPDxxYU6=
SNU-5 M1Lqemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnYb4c4Omh? M3PyTWROW09? M{fkO2lEPTB;MT6zOVHDuTBwMEmx{txO M{fNXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUW5PFE1Lz5{MkG1PVgyPDxxYU6=
SNU-638 NYCwR4FxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHywOXE4Omh? MlTwSG1UVw>? MoHQTWM2OD1{LkK4NuKyOC5yNUROwG0> NX:zSnp7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOVk5OTRpPkKyNVU6QDF2PD;hQi=>
SNU-16 MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnoT4FWPzKq NXmxeoU2TE2VTx?= NX7kcGQ4UUN3ME2xMlU4O8LzMD6wNFHPxE1? NXr1OGNJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOVk5OTRpPkKyNVU6QDF2PD;hQi=>
SNU-484 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;1dWI4Omh? MV3EUXNQ MYrJR|UxRTFwN{K4xtExNjB2Nd88US=> NW[4XJdmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOVk5OTRpPkKyNVU6QDF2PD;hQi=>
SNU-620 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mly2O|Jp NGnlV3NFVVOR NH22emVKSzVyPUKuPVM6yrFyLkCwNe69VQ>? MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF3OUixOEc,OjJzNUm4NVQ9N2F-
SNU-719 M{\mO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVm3Nog> NEfo[IpFVVOR MneyTWM2OD1|LkCzO:KyOC5yM{NOwG0> M3vjVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUW5PFE1Lz5{MkG1PVgyPDxxYU6=
MM cell lines NIPwWmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYixNO69VQ>? MWSyOIg> NX32PIVHTE2VTx?= M1LKfWlEPTBidnHybYV{KGGvb37nJIRq\m[ncnXueEBk\WyuIHzpcoV{KGmwIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y5k\Q>? NX3xTXRRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNFc1QDVpPkKyNlA4PDh3PD;hQi=>
ARP-1 NUf2eI9nSXCxcITvd4l{KEG|c3H5 M{[4bFEx|ryP Mom2NlRp M{DIT2ROW09? MX3pcoR2[2W|IF3NJINmdGxiYYDvdJRwe2m|IITodo92\2hiY3HzdIF{\SCjY4TpeoF1cW:w NUPYUm9iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNFc1QDVpPkKyNlA4PDh3PD;hQi=>
colon cancer cell lines NHS4SmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnj[XhIOC1zMN88US=> NVriZ4Z5PzKq MW\EUXNQ M1yyPWlEPTB;Md88US=> MkTOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NEO4OVcoRjJ{NUSzPFU4RC:jPh?=
gastric cancer cell lines M2rHTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljvNE0yOM7:TR?= NXq5W2lRPzKq NEjvUWxFVVOR M33OR2lEPTB;Mj21{txO MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV2M{i1O{c,OjJ3NEO4OVc9N2F-
HCT-116/HT-29/MKN-45 MXvBdI9xfG:|aYOgRZN{[Xl? NHzEeo4z|ryP NIq5Vo41QGh? NUTac2lRe2irZoSgbY4hTzJicHjhd4U> MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV2M{i1O{c,OjJ3NEO4OVc9N2F-
HT-29 and HCT-116 M2G3dGNie3Cjc3WgZZN{[Xl? MofUOe69VQ>? NH;3co0zPGh? NW\Sfm5QcW6mdXPld{Bk[XOyYYPlJIFkfGm4aYT5 NY\FRYdVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OFM5PTdpPkKyOVQ{QDV5PD;hQi=>
PIK3CA-mutant MCF7 NXnrVmlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHCS2k2OD1zNkFCtVkydk4xvJzMSFUxRTl6MNMxNlc{dk1? Mn22O|Jp M13vc2dKPTB;MU[wxtE6OW6P78{MUGQ2OD17OEFCtVI4O26P NGjEemE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[1N|k3Pyd-MkK2OVM6Pjd:L3G+
PIK3CA-mutant MCF7 NUHFWHNuU2mwYYPlJGF{e2G7 NYDqUJdiUUN3ME2xNVTDuTOwTR?= MknrO|Jp NGDNXI5KSzVyPUGxOOKyO26PIHnuJJJm\HWlaX7nJGFsfCCyaH;zdIhwenmuYYTpc44hdGW4ZXzz NIT5XWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[1N|k3Pyd-MkK2OVM6Pjd:L3G+
MCF7-myr-Akt MlLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzHTVUxRTJ7OdMxOlhvVe,:jFzEOVDwxJ5zMDywNFBvVQ>? M1Ty[|czcA>? NGr1OYJIUTVyPUK5PeKyPjiwTf-8kGxFPTExvK6xNEwxODCwTR?= NXewbFh7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2OVM6PjdpPkKyOlU{QTZ5PD;hQi=>
Y1 cell line NHPs[GJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVewMlHPxE1xMd88US=> Mo[3NlRp NUC2WHVYTE2VTx?= M33IOIlvcGmkaYTzJFYx97zHIHPlcIwhfmmjYnnsbZR6KGmwIF35Z{1U[3S{LYTyZY5{\mWldHXkJINmdGy| M1vKVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NkmyPVA1Lz5{Mk[5NlkxPDxxYU6=
human NSCLC MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37vPVAvPS1{zszN MWK3Nog> M4Wxd2lEPTB;Md88US=> M{P0elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{ixN|k{Lz5{Mke4NVM6OzxxYU6=
human NSCLC M{nuRmtqdmG|ZTDBd5NigQ>? MoT3Ne69VQ>? MVmyOIg> M1G4WIlvcGmkaYTzJJRp\SCDa4SvcXRQWiC|aXfuZYxqdmdicHH0bJdigSCjdDCzbEBi\nSncjD0doVifG2nboS= NHLtZ|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke4NVM6Oyd-MkK3PFE{QTN:L3G+
JVM2 NXjUTItmS3m2b4TvfIlkcXS7IHHzd4F6 M{WxNlAvOi1{MN88US=> MmDlO|Jp MVXEUXNQ MofzTWM2OD1yLkpOwG0> Mne2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{M{i2N|koRjJ|MkO4OlM6RC:jPh?=
EHEB M4DwZ2N6fG:2b4jpZ4l1gSCjc4PhfS=> MYSwMlIuOjEQvF2= MmqxO|Jp NHfZNGJFVVOR M1q1UmlEPTB;MD63{txO NHiwfJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KzPFY{QSd-MkOyN|g3Ozl:L3G+
MEC2 Ml7yR5l1d3SxeHnjbZR6KGG|c3H5 NIrIUFUxNjJvMkFOwG0> NGT2TlU4Omh? NX6wNWZ4TE2VTx?= NXPGRYdMUUN3ME2wMlfPxE1? M1jTdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MkO4OlM6Lz5{M{KzPFY{QTxxYU6=
primary B-CLL lymphocytes MlPVRZBweHSxc3nzJGF{e2G7 NGrFe3lKSzVyIH\vdkBm[WOqIIDybY1ienliY3XscEBtcW6n MnvJNlRp MmfBSG1UVw>? MUDJR|Ux97zeM988UUBnd3JiYXzsJJBifGmnboTz MkXyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{M{i2N|koRjJ|MkO4OlM6RC:jPh?=
primary B-CLL lymphocytes NWjtR4VWU2mwYYPlJGF{e2G7 NE\sSndKSzVyIH\vdkBm[WOqIIDybY1ienliY3XscEBtcW6n M2PvVlI1cA>? MXfpcohq[mm2czDwO|BUPktiJjC0SU1DWDFiZYjwdoV{e2mxbh?= MlXlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{M{i2N|koRjJ|MkO4OlM6RC:jPh?=
SK-HEP1 NFvIe45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXuxMVIx|ryP MV63Nog> NFOz[5dFVVOR MXvJR|Ux97zeMd88US=> Mm\qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2N{mxN|YoRjJ|NEe5NVM3RC:jPh?=
786-0 MlrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvuV2c6OS1{MN88US=> NX64V5ZjPzKq MmLXSG1UVw>? M4q5[mlEPTExvKyx{txO NEC1foc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S3PVE{Pid-MkO0O|kyOzZ:L3G+
human HCC cell lines MVHD[YxtKH[rYXLpcIl1gSCjc4PhfS=> NX\OZXFzOC5yMEWtNe69VQ>? M1jwSFQ5cA>? NUPPUoMzUUN3ME2x{txO M1LLV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NEi5PVk6Lz5{M{S4PVk6QTxxYU6=
Huh7 MVnLbY5ie2ViQYPzZZk> M1;wcFHPxE1? MVO0PIg> M3uy[ZNq\26r77{BZ4FvfGy7IILl[JVk\XNicHjvd5Bpd3K7bHH0bY9vKG:oIFHreC=> NVrpdJk3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PFk6QTlpPkKzOFg6QTl7PD;hQi=>
human NSCLC cell lines NIPYPVZCeG:ydH;zbZMhSXO|YYm= MlmzNE4yOjVvNN88US=> MXWyOIg> Ml3oSG1UVw>? NX;J[I16UUN3MIOgdoFv\2W|IH\yc40hOC52LUNOwG0> NETrUmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W2NlQ4Oid-MkO1OlI1PzJ:L3G+
Primary CLL cells NFHyNlRCeG:ydH;zbZMhSXO|YYm= M{P0VVEuOTEQvF2= MW[0PIg> NV3Mc3ppcW6mdXPld{BieG:ydH;zbZMhcW5iQ1zMJINmdGy|IHnu[IVx\W6mZX70JI9nKHC{b3fuc5N1cWNibXHyb4Vzew>? Ml\qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NUC4NFcoRjJ|OEWwPFA4RC:jPh?=
Primary CLL cells NFnQPXBMcW6jc3WgRZN{[Xl? NHfI[Wwz|ryP NU\1TpY4OzCvaX6= MlvW[IVkemWjc3XkJHBKO0tiYXP0bZZqfHl? MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh3MEiwO{c,OjN6NUC4NFc9N2F-
Primary CLL cells MmW5R5l1d3SxeHnjJGF{e2G7 Ml;qNu69VQ>? MojCNlRp NV:4WWlucW6mdXPld{Bk\WyuIHP5eI91d3irY3n0fS=> MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh3MEiwO{c,OjN6NUC4NFc9N2F-
LC-1/SQSF M{G0[mZ2dmO2aX;uJGF{e2G7 NHP5R3A{|ryP MmHpNlRp NWK1ZmYxTE2VTx?= M1vBR4Rm[3KnYYPlJG5TTjJicILveIVqdiCuZY\lcC=> NHK5XWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m4NFA6Oyd-MkO5PFAxQTN:L3G+
BCR-ABL MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnK3NE4zPS1zMN88US=> NVrzU45EPGR? MmjOd4lodmmoaXPhcpRtgSCrbnjpZol1KGOnbHygdJJwdGmoZYLheIlwdg>? MnTNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NES2NVIoRjJ2MkS0OlEzRC:jPh?=
T-ALL NGi3S4VCeG:ydH;zbZMhSXO|YYm= NG\qOFJj\XS5ZXXuJFEvPCCjbnSgOU4{KG2PIHH0JFI1cCCjbnSgNE46KGGwZDC1MlUhdU1iYYSgOFhpKGmwIHTp[oZmemWwdDDj[YxtKGyrbnW= NGqwWW8zPCCxcjC0PIg> MYfEUXNQ NYqyc49R[W[oZXP0d{B1cGViUFmzT{Bx[XSqd3H5JIlvKFRvQVzMJINmdGxibHnu[ZM> NXn1[oxHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNVA4OzZpPkK0N|ExPzN4PD;hQi=>
H1975 M3jyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDOdWprOC5|LUmuOu69VQ>? NFHv[Is4Omh? NGrmSo9FVVOR MWTJR|UxRTFwM{i1{txO Ml7IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|M{e4OFYoRjJ2M{O3PFQ3RC:jPh?=
H1975 NEmzeG5CeG:ydH;zbZMhSXO|YYm= NIf4SFIz|ryP M2DofVI1cA>? M17OU2ROW09? NUfMdHJUcW6lcnXhd4V{KGGyb4D0c5NqeyC{YYTlJJNq\26rZnnjZY51dHl? M2rnVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{O3PFQ3Lz5{NEOzO|g1PjxxYU6=
BON M362OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLGNU02|ryP M3\TU|czcA>? MYrk[YNz\WG|ZYOgZ4VtdCCycn;sbYZmemG2aX;u NXTkZm11RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0OFM2OjNpPkK0OFQ{PTJ|PD;hQi=>
BON NGDIOnNCeG:ydH;zbZMhSXO|YYm= M2PUOFEuPc7:TR?= MlrvNlRp M4f4e4lv[3KnYYPld{BieG:ydH;zbZM> NELNNXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES0N|UzOyd-MkS0OFM2OjN:L3G+
GBM M1LhZmFxd3C2b4Ppd{BCe3OjeR?= MmjENu69VQ>? MW[0PIg> MmXPSG1UVw>? NYLtXHlucW6mdXPl[EBpcWeqZYKgcIV3\Wy|IH;mJIFxd3C2b4Ppd{wh[W6mIHTlZ5Jm[XOnZDDj[YxtKH[rYXLpcIl1gQ>? NVXIcVRjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1NFA1QTJpPkK0OVAxPDl{PD;hQi=>
FaDu MYnGeY5kfGmxbjDBd5NigQ>? M3rWOlUh|ryP NUTNZ2xyOjRiaB?= MlPzSG1UVw>? Mmr1VoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36= M3zFXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkOxNVQ4Lz5{NE[zNVE1PzxxYU6=
EMT6 MVXGeY5kfGmxbjDBd5NigQ>? M1HETVUh|ryP NGnLRoEzPCCq M1P6PGROW09? MnjsVoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36= MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ|MUG0O{c,OjR4M{GxOFc9N2F-
HCT116 MXzGeY5kfGmxbjDBd5NigQ>? MnK5OUDPxE1? Mn7ONlQhcA>? NV\vVHhHTE2VTx?= NEO2[ZZT\WS3Y3XzJI95gWenbjDjc45{fW2ydHnvci=> NHTafnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zNVE1Pyd-MkS2N|EyPDd:L3G+
U87 M2\sbGZ2dmO2aX;uJGF{e2G7 MUW1JO69VQ>? MkiyNlQhcA>? NYOxd4JDTE2VTx?= MoiwVoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36= MkTzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4M{GxOFcoRjJ2NkOxNVQ4RC:jPh?=
Saos-2 MkXNSpVv[3Srb36gRZN{[Xl? M4PZTVUxKM7:TR?= MmPmOFghcA>? NFL6OZRKdmirYnn0d{Bk\WyuIHnueoF{cW:w MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{N{[2NEc,OjR5Mke2OlA9N2F-
MG-63 Mnv5SpVv[3Srb36gRZN{[Xl? NYLXdlk4PTBizszN M13wS|Q5KGh? MV3Jcohq[mm2czDj[YxtKGmwdnHzbY9v NV\6U5JJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3Nlc3PjBpPkK0O|I4PjZyPD;hQi=>
SJSA-1 MWHGeY5kfGmxbjDBd5NigQ>? NXLhSWs5PTBizszN Ml;iOFghcA>? NWP6UVFNUW6qaXLpeJMh[2WubDDpcpZie2mxbh?= M135fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{K3OlYxLz5{NEeyO|Y3ODxxYU6=
Saos-2 NXKzWYt3TnWwY4Tpc44hSXO|YYm= NEDTZVE2OCEQvF2= NIH2bGI1QCCq NXzGNolwUW6qaXLpeJMhdWG2cnn4JI1mfGGubH;wdo91\WmwYYPlMVIh\XiycnXzd4lwdg>? M{LPeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{K3OlYxLz5{NEeyO|Y3ODxxYU6=
MG-63 MU\GeY5kfGmxbjDBd5NigQ>? NFL2R3I2OCEQvF2= Mk\vOFghcA>? NVnmVYw5UW6qaXLpeJMhdWG2cnn4JI1mfGGubH;wdo91\WmwYYPlMVIh\XiycnXzd4lwdg>? NGrENW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyO|Y3OCd-MkS3Nlc3PjB:L3G+
SJSA-1 MlHtSpVv[3Srb36gRZN{[Xl? MmrMOVAh|ryP NX\R[Jl2PDhiaB?= NXvYc|hWUW6qaXLpeJMhdWG2cnn4JI1mfGGubH;wdo91\WmwYYPlMVIh\XiycnXzd4lwdg>? MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{N{[2NEc,OjR5Mke2OlA9N2F-
Saos-2 NGfVOG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPNdJc2OCEQvF2= Mn;oOFghcA>? NW[5flN1UW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= NInNUVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyO|Y3OCd-MkS3Nlc3PjB:L3G+
MG-63 MoXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;aXYJSPTBizszN MlzMOFghcA>? NUDSfWlPUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= NH\URY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyO|Y3OCd-MkS3Nlc3PjB:L3G+
SJSA-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIr5Roc2OCEQvF2= MoDVOFghcA>? Mmf2TY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? M4XEXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{K3OlYxLz5{NEeyO|Y3ODxxYU6=
LN18 NFvBUnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVeyNEDPxE1? MWO3NkBp MnrUSG1UVw>? Mk\kTWM2ODx3IN88US=> NYTEb217RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFExPzRpPkK0O|QyODd2PD;hQi=>
LN229 NFjLdY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXZRWRyOjBizszN MnrnO|IhcA>? MonoSG1UVw>? MUnJR|UxRDVizszN MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2MUC3OEc,OjR5NEGwO|Q9N2F-
LNZ308 MnTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrsOY4{OjBizszN NXn6OFRWPzJiaB?= MUHEUXNQ NXTJNYtQUUN3MEy1JO69VQ>? NUjXb5p1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFExPzRpPkK0O|QyODd2PD;hQi=>
T98G NIDJOVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PWe|IxKM7:TR?= MorUO|IhcA>? NFLjSnhFVVOR NYXrZXZmUUN3MEy1JO69VQ>? MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2MUC3OEc,OjR5NEGwO|Q9N2F-
U87 MkW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;HVlIxKM7:TR?= MnHhO|IhcA>? MYTEUXNQ MXTJR|UxRDVizszN NE\SOmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0NVA4PCd-MkS3OFExPzR:L3G+
LN18 M3XvWmZ2dmO2aX;uJGF{e2G7 M3PRN|Uh|ryP NUKwcpNyOjRiaB?= M17sWmROW09? NUfKTFZ3UW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?= M4D2fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{SxNFc1Lz5{NEe0NVA4PDxxYU6=
LNZ308 NF;rW3pHfW6ldHnvckBCe3OjeR?= NELCfIY2KM7:TR?= NFXm[HczPCCq NFzTfm5FVVOR MlTITY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>? NVrk[VV[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFExPzRpPkK0O|QyODd2PD;hQi=>
MDA-MB-175 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGG4do8yKM7:TR?= MoDUOUBl NGqzS|hFVVOR NFflW2RKSzVyPEGg{txO NGrMfJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O|k4QTZ:L3G+
MDA-MB-134 NFvvT|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHFdWoyKM7:TR?= NFnVRYM2KGR? NVLITnd4TE2VTx?= MkHETWM2ODxzIN88US=> MnT5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O|k3RC:jPh?=
HCC1500 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\wNUDPxE1? MYS1JIQ> NYX1bXF2TE2VTx?= MorzTWM2ODxzIN88US=> M4DNVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O|k3Lz5{NEi3PVc6PjxxYU6=
EFM-19 NF7hXodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYixJO69VQ>? NHnTcoQ2KGR? M1LRPWROW09? NWXsToxGUUN3MEyxJO69VQ>? Ml;1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O|k3RC:jPh?=
ZR-75-30 M1XH[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPoXosyKM7:TR?= MlvROUBl NV3sVWFiTE2VTx?= NHTw[HVKSzVyPEGg{txO NF71b4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O|k4QTZ:L3G+
MDA-MB-361 MlS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3L2XFEh|ryP MkToOUBl Mle0SG1UVw>? Mn;XTWM2ODxzIN88US=> M{XuUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O|k3Lz5{NEi3PVc6PjxxYU6=
T-47D MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr0TFUyKM7:TR?= MUm1JIQ> NVXFOm9sTE2VTx?= NITGd|NKSzVyPEGg{txO MkX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O|k3RC:jPh?=
SK-BR-3 M1HRc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHxbJZUOSEQvF2= MkXGOUBl M2TjN2ROW09? NWjKV|ZVUUN3MEyxJO69VQ>? MkOzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O|k3RC:jPh?=
UACC-732 NGrPS3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPlNUDPxE1? NXTIV49jPSCm M2i4SGROW09? M4D2RWlEPTB:MTFOwG0> MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
BT-474 NEK5W4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7rZmsyKM7:TR?= NXjQdnJ6PSCm NY\MbVh4TE2VTx?= M2PLOGlEPTB:MTFOwG0> NYrDcVBZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|k4QTZpPkK0PFc6Pzl4PD;hQi=>
HCC202 NIPLSlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXL6U2tzOSEQvF2= MUe1JIQ> MlXoSG1UVw>? MmrXTWM2ODxzIN88US=> MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
MCF7 MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVWxJO69VQ>? NG[1R|M2KGR? M2DkRmROW09? M2fS[mlEPTB:MTFOwG0> M1LURVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O|k3Lz5{NEi3PVc6PjxxYU6=
MDA-MB-415 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUexJO69VQ>? MmTHOUBl NYnFb5pkTE2VTx?= NVrMSZdSUUN3MEyxJO69VQ>? MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
MDA-MB-453 NFPxU4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmOxNUDPxE1? M1O5SFUh\A>? MWjEUXNQ MVPJR|UxRDFizszN NG\UWGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O|k4QTZ:L3G+
ZR-75-1 NGraTGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWSxJO69VQ>? M4T6TlUh\A>? NFTNV2pFVVOR MYXJR|UxRDFizszN NUDzWIFoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|k4QTZpPkK0PFc6Pzl4PD;hQi=>
HCC38 M1zkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Tyb|Eh|ryP NIjSdmI2KGR? NUDTTo1HTE2VTx?= M1TxfGlEPTB:MTFOwG0> MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
HCC1419 M1LFbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTEUIpsOSEQvF2= MnPlOUBl Mof3SG1UVw>? NVvIUmVFUUN3MEyxJO69VQ>? NFfubJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O|k4QTZ:L3G+
UACC-812 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTMcXZ5OSEQvF2= MYO1JIQ> M4q0XmROW09? MWLJR|UxRDFizszN NVHPZ5k5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|k4QTZpPkK0PFc6Pzl4PD;hQi=>
HCC1187 MnPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfINWsyKM7:TR?= MUW1JIQ> NGnCbnpFVVOR MYPJR|UxRDFizszN NUXvUGFpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|k4QTZpPkK0PFc6Pzl4PD;hQi=>
KPL-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XHWFEh|ryP M3faflUh\A>? M3LKcGROW09? NVvtfm15UUN3MEyxJO69VQ>? NFXXRZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O|k4QTZ:L3G+
SUM-225 NX;qe3RDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoThNUDPxE1? MXq1JIQ> M4HJRmROW09? M4rxcmlEPTB:MTFOwG0> NWrBPFhkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|k4QTZpPkK0PFc6Pzl4PD;hQi=>
EFM-192A NHvpOWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\YPFEh|ryP M4jWVVUh\A>? NYrXVG5PTE2VTx?= NWHOWnMyUUN3MEyxJO69VQ>? MoHPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O|k3RC:jPh?=
JIMT-1 NV6xfWpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHodG0yKM7:TR?= MnroOUBl MX7EUXNQ M2XoXWlEPTB:MTFOwG0> NUXib5p{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|k4QTZpPkK0PFc6Pzl4PD;hQi=>
HCC1143 MkDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHMNUDPxE1? MWe1JIQ> MkizSG1UVw>? MWrJR|UxRDFizszN M2rITFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O|k3Lz5{NEi3PVc6PjxxYU6=
HCC2218 NXXQRo9DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIKwO2kyKM7:TR?= MV61JIQ> MUXEUXNQ MoTyTWM2ODxzIN88US=> NYi5T3h5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|k4QTZpPkK0PFc6Pzl4PD;hQi=>
MDA-MB-468 MmGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPxemFMOSEQvF2= MmfhOUBl MkfYSG1UVw>? M3zwN2lEPTB:MTFOwG0> NUjzZpUzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|k4QTZpPkK0PFc6Pzl4PD;hQi=>
BT-20 M2HObWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M171[VEh|ryP M2Xz[lUh\A>? NGryb2tFVVOR M3TKb2lEPTB:MTFOwG0> MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
MDA-MB-435 NHfHUlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\JNUDPxE1? NW\3ZWRkPSCm MlS2SG1UVw>? NIjUcoNKSzVyPEGg{txO M1rIPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O|k3Lz5{NEi3PVc6PjxxYU6=
BT-549 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLNN5YyKM7:TR?= NGDyfmY2KGR? MUjEUXNQ NX;HSotpUUN3MEyxJO69VQ>? MmHtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O|k3RC:jPh?=
HCC1806 MnHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnmWZdEOSEQvF2= Ml75OUBl MlTQSG1UVw>? MofhTWM2ODxzIN88US=> NEC5OYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O|k4QTZ:L3G+
HCC1937 NI\0U5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkn6NUDPxE1? MVm1JIQ> M{jPPWROW09? NUXhUW9EUUN3MEyxJO69VQ>? NHHETFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O|k4QTZ:L3G+
Hs578T NHHQb5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV2xJO69VQ>? M2DWZVUh\A>? M1PiZmROW09? MnLpTWM2ODxzIN88US=> NFfuSFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O|k4QTZ:L3G+
MCF7 NWW1do9vS3m2b4TvfIlkKEG|c3H5 M4POcFczKGh? Mn\ZSG1UVw>? MkPpR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BmgHC{ZYPzbY5oKFCLM1vhcJBp[SCHNUS1T{BufXSjboSge4l1cCCJSUWwJI9nKDBwMECwNVU5KM7:TR?= MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEK2Okc,OjR7MECyOlY9N2F-
DU145 M{W1XmN6fG:2b4jpZ{BCe3OjeR?= MoTxO|IhcA>? NYfxZ4N2TE2VTx?= M{LiRmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGW6cILld5NqdmdiTFvCNUBufXSjboSge4l1cCCJSUWwJI9nKDBwMECwOFM2KM7:TR?= NWTFOlRuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFAzPjZpPkK0PVAxOjZ4PD;hQi=>
A2780 MoLvR5l1d3SxeHnjJGF{e2G7 MnvzO|IhcA>? M2G0W2ROW09? M1S3bGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KFCWRV6t[IVncWOrZX70JIh2dWGwIFGyO|gxKGOnbHzzJJdqfGhiR1m1NEBw\iByLkCwNFY{PSEQvF2= NGHtUIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFI3Pid-MkS5NFAzPjZ:L3G+
U87MG Mon1R5l1d3SxeHnjJGF{e2G7 NIHOWoQ4OiCq MkfJSG1UVw>? M2jVdWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KFCWRV6t[IVncWOrZX70JIh2dWGwIGW4O21IKGOnbHzzJJdqfGhiR1m1NEBw\iByLkCwNFY6QCEQvF2= MoeyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MECyOlYoRjJ2OUCwNlY3RC:jPh?=
A2780 NV\COHRqTnWwY4Tpc44hSXO|YYm= MVyxJIg> NIDLfW1FVVOR NFXhd3hKdmirYnn0bY9vKG:oIGDJN2sudWWmaXH0[YQhSUuWIGPldlQ4OyCyaH;zdIhwenmuYYTpc44hf2m2aDDFR|UxKG:oIECuNFU2KM7:TR?= MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEK2Okc,OjR7MECyOlY9N2F-
DU145 MYXGeY5kfGmxbjDBd5NigQ>? NUjo[pJNOSCq MW\EUXNQ M2r6b2lvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBFXTF2NTDj[YxteyCqYYLic5JqdmdiTFvCNUBufXSjdHnvckB4cXSqIFXDOVAhd2ZiMD6wO|Mh|ryP NWezco9URGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFAzPjZpPkK0PVAxOjZ4PD;hQi=>
A2780 M3LwVGZ2dmO2aX;uJGF{e2G7 NH\Ed2syKGh? NFvI[4RFVVOR MWPJcohq[mm2aX;uJI9nKFCLM1utcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:|cHjvdplt[XSrb36gbY4hWFSHTj3k[YZq[2mnboSgbJVu[W5iQUK3PFAh[2WubIOge4l1cCCHQ{WwJI9nKDBwMEe0JO69VQ>? M2r2b|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwNlY3Lz5{NEmwNFI3PjxxYU6=
MCF7 MlHSSpVv[3Srb36gRZN{[Xl? NUS2fHp3OSCq NEnyOlBFVVOR NFTWSJlKdmirYnn0bY9vKG:oIGDJN2tidHCqYTDFOVQ2UyCvdYThcpQudWWmaXH0[YQhSUuWIGPldlQ4OyCyaH;zdIhwenmuYYTpc44hf2m2aDDFR|UxKG:oIECuNUDPxE1? NVz4UVIxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFAzPjZpPkK0PVAxOjZ4PD;hQi=>
U87MG NF;sZ2pHfW6ldHnvckBCe3OjeR?= MkDvNUBp NWTwUI1nTE2VTx?= NFfGXVlKdmirYnn0bY9vKG:oIGDJN2sudWWmaXH0[YQhSUuWIGPldlQ4OyCyaH;zdIhwenmuYYTpc44hcW5iUGTFUk1l\W[rY3nlcpQhcHWvYX6gWVg4VUdiY3XscJMhf2m2aDDFR|UxKG:oIECuNVMh|ryP M3vWT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwNlY3Lz5{NEmwNFI3PjxxYU6=
A2780 NUDLUXhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELydmY4OiCq NWnTZ3Q1TE2VTx?= NFGyUHJGSzVyPUCuOVIh|ryP NUTIZnRYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFAzPjZpPkK0PVAxOjZ4PD;hQi=>
Huh7 M2jtNWZ2dmO2aX;uJGF{e2G7 MV[xJO69VQ>? MmDtNUBp MUnEUXNQ M33LWGlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1RiYYSgV4VzPDd2 NF;IS2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwOFQxOyd-MkWwNFQ1ODN:L3G+
BNL NEjtV21HfW6ldHnvckBCe3OjeR?= NE\6ZosyKM7:TR?= MoXGNUBp NFzy[I9FVVOR M4rsVmlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBUPg>? MnnWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMES0NFMoRjJ3MEC0OFA{RC:jPh?=
BON-1 NFjQOZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID3U3A2ODBibl2= MVixNEBl NWDmVndrTE2VTx?= MlvxTY5pcWKrdIOgZ4VtdCCpcn;3eIg> MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB{NkK5Nkc,OjVyMk[yPVI9N2F-
BON-1 MYTGeY5kfGmxbjDBd5NigQ>? M2PVXVUxOCCwTR?= MYC0JIg> NWXCPItITE2VTx?= MX3Jcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtVKGG2IGTodlMxQCCjbnSgV4VzPDd| NIKzeJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCyOlI6Oid-MkWwNlYzQTJ:L3G+
QGP-1 NUnyfFh2TnWwY4Tpc44hSXO|YYm= MW[1NFAhdk1? M3TDe|QhcA>? NX3INGlMTE2VTx?= NGLsS5FKdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhSUuWIHH0JHRpejNyODDhcoQhW2W{NEez M1\u[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEK2NlkzLz5{NUCyOlI6OjxxYU6=
HCT-15 M1jESmFxd3Sxc3nzJGF{e2G7 NUPHZnROOTBizszN MoPaOFghcA>? MmX1SG1UVw>? NXvlO3hJUW6mdXPld{BieG:ydH;zbZMhcW5iSFPUMVE2KGOnbHzzJIhiemKxdYLpcochWEmNM1PBJIhwfHOyb4SgcZV1[XSrb36= M3rPU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWyNlQ2Lz5{NUG1NlI1PTxxYU6=
HCT-116 NIG3UY1CeG:2b4Ppd{BCe3OjeR?= M3LtTlExKM7:TR?= MXO0PEBp NFfGU5FFVVOR NYGzfI1pUW6mdXPld{BieG:ydH;zbZMhcW5iSFPUMVEyPiClZXzsd{Bp[XKkb4XybY5oKFCLS{PDRUBpd3S|cH;0JI12fGG2aX;u NHTPSIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG1NlI1PSd-MkWxOVIzPDV:L3G+
NCI-H460 MnfPRZBwfG:|aYOgRZN{[Xl? MYKxNEDPxE1? NUOyWHlWPDhiaB?= M3;BW2ROW09? MoHFTY5lfWOnczDhdI9xfG:|aYOgbY4hVkOLLVi0OlAh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= NXuzfXh3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOVIzPDVpPkK1NVUzOjR3PD;hQi=>
SKOV-3 M2C3T2Fxd3Sxc3nzJGF{e2G7 NEjHRYgyOCEQvF2= MXK0PEBp NY\iSlg6TE2VTx?= Mn7QTY5lfWOnczDhdI9xfG:|aYOgbY4hW0uRVj2zJINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? M3zvRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWyNlQ2Lz5{NUG1NlI1PTxxYU6=
BSY-1 MkDJRZBwfG:|aYOgRZN{[Xl? NGTheFgyOCEQvF2= MX[0PEBp NH7lVYRFVVOR NV\odWdTUW6mdXPld{BieG:ydH;zbZMhcW5iQmPZMVEh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= M3fXclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWyNlQ2Lz5{NUG1NlI1PTxxYU6=
MKN-1 M4ridGFxd3Sxc3nzJGF{e2G7 NULLOGtxOTBizszN MXG0PEBp MVnEUXNQ MX;JcoR2[2W|IHHwc5B1d3OrczDpckBOU05vMTDj[YxteyCqYYLic5VzcW6pIGDJT|NESSCqb4TzdI91KG23dHH0bY9v Ml;GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNUKyOFUoRjJ3MUWyNlQ2RC:jPh?=
NCI-H522 MmOzRZBwfG:|aYOgRZN{[Xl? NWrvfGtOOTBizszN NFfHOog1QCCq NHjhZmhFVVOR NYHHS29YUW6mdXPld{BieG:ydH;zbZM> NFX3Xpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG1NlI1PSd-MkWxOVIzPDV:L3G+
OVCAR-3 MUjBdI91d3OrczDBd5NigQ>? M4nxXlExKM7:TR?= MXq0PEBp NWPaUWl5TE2VTx?= MUTJcoR2[2W|IHHwc5B1d3Orcx?= M1fufVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWyNlQ2Lz5{NUG1NlI1PTxxYU6=
HBC-5 MnfrRZBwfG:|aYOgRZN{[Xl? NV;PcpQ{OTBizszN NIe1XGg1QCCq MmPDSG1UVw>? MYDJcoR2[2W|IHHwc5B1d3Orcx?= M{X4O|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWyNlQ2Lz5{NUG1NlI1PTxxYU6=
RXF-631L MoTpRZBwfG:|aYOgRZN{[Xl? MVSxNEDPxE1? M3\uT|Q5KGh? NETrXnNFVVOR M4G3[mlv\HWlZYOgZZBweHSxc3nz M2nEZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWyNlQ2Lz5{NUG1NlI1PTxxYU6=
MKN-45 MnmyRZBwfG:|aYOgRZN{[Xl? MUSxNEDPxE1? M12yfVQ5KGh? NWj3cpllTE2VTx?= NYPKT2xYUW6mdXPld{BieG:ydH;zbZM> MojBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNUKyOFUoRjJ3MUWyNlQ2RC:jPh?=
LNCaP NInHelRHfW6ldHnvckBCe3OjeR?= MoW3NUDPxE1? NUftXnZ4W3WycILld5NmeyCyLVHLWEBt\X[nbIO= NFnyOok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO2NFc6QSd-MkWzOlA4QTl:L3G+
LNCaP95 M{HYeGZ2dmO2aX;uJGF{e2G7 NHLrUIsyKM7:TR?= NV\ubVVyW3WycILld5NmeyCyLVHLWEBt\X[nbIO= M{\G[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{[wO|k6Lz5{NUO2NFc6QTxxYU6=
A549 NH\qXo5HfW6ldHnvckBCe3OjeR?= MXy1NFAhdk1? NYPpe5NOPDhiaB?= NF7tZlhFVVOR MoHnTY5pcWKrdIOgRYt1KGGldHn2ZZRqd25? NETYU|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmzO|I6QSd-MkW5N|czQTl:L3G+
A549 M4DafGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHuNUDPxE1? NFvNd4E4OiCq M2HoN2ROW09? MYrJcohq[mm2czDj[YxtKGe{b4f0bC=> NVX3OIpURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5N|czQTlpPkK1PVM4Ojl7PD;hQi=>
H522 M3:5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHPdmwyKM7:TR?= MlXNO|IhcA>? MkjLSG1UVw>? MmTUTY5pcWKrdIOgZ4VtdCCpcn;3eIg> MnuwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7M{eyPVkoRjJ3OUO3Nlk6RC:jPh?=
SKMES-1 NWLjVY5iS3m2b4TvfIlkKEG|c3H5 NETEfmIyKM7:TR?= M3fOR|czKGh? NIjyd4NKdmS3Y3XzJINmdGxiZHXheIg> NWmyOldmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNVM{OThpPkK2NFE{OzF6PD;hQi=>
H596 NX\vXWFlTnWwY4Tpc44hSXO|YYm= NYm4WXY{OSEQvF2= NXy2U3pPUW2yYXnyd{Bk\WyuIH3p[5JifGmxbh?= MlPQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMUOzNVgoRjJ4MEGzN|E5RC:jPh?=
HCC2450 MWjGeY5kfGmxbjDBd5NigQ>? NXfvbndROSEQvF2= MortTY1x[Wm{czDj[YxtKGmwdnHzbY9v MnvzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMUOzNVgoRjJ4MEGzN|E5RC:jPh?=
HCT116 MkHlRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NWDjWIR{PzJiaILz M3jQfGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCwMlQ5KM7:TT6= MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4NUmwPUc,OjV5NkW5NFk9N2F-
MCF7 NHvLWJRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NXzhR5BpPzJiaILz MUPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDFizszNMi=> NGDpbpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2OVkxQSd-MkW3OlU6ODl:L3G+
U87MG NH\vdW9CdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M3PpW|czKGi{cx?= NXq0eWVsSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPFdOTyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNU43PCEQvF2u M{TLTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[1PVA6Lz5{NUe2OVkxQTxxYU6=
A549 NETYTppCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NGW4XXM4OiCqcoO= MlzlRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDNUS5JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB{LkC3JO69VS5? NGLPT2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2OVkxQSd-MkW3OlU6ODl:L3G+
HeLa MYfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M3rnV|czKGi{cx?= NIHGS2JCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjlUIEh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IESuN|Qh|ryPLh?= NXGyZZN3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlU6ODlpPkK1O|Y2QTB7PD;hQi=>
HCT116 MVfGeY5kfGmxbjDhd5NigQ>? MYCxNEB2VQ>? NIPXVoQyKGi{ NFHHOHJKdmirYnn0bY9vKG:oIGDJN2swSWu2IHnuJIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyCDa4SgdIhwe3Cqb4L5cIF1cW:wIHH0JFExKHWPIHHmeIVzKDFiaIKgZpkhX2W|dHXyckBjdG:2dHnu[{BidmGueYPpdy=> NU\ZbY01RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlU6ODlpPkK1O|Y2QTB7PD;hQi=>
A2058 melanoma NEDhfIdE\WyuIHP5Z4xmKGG|c3H5 M4jPPFUhfU1? M3vEfFI1KGi{cx?= M1iwe2NmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJGEzODV6IH3lcIFvd22jIHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBifCCVdXLHNUBxcGG|ZTDheEA2KHWPIHHmeIVzKDJ2IHjyd{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oKGKjc3XkJGZCS1NiYX7hcJl{cXN? NUPkXHVtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4Nlk2QTJpPkK4PFI6PTl{PD;hQi=>
A2058 melanoma NXfyVlRqS2WubDDjfYNt\SCjc4PhfS=> NUHvdFhlPSC3TR?= NVK5Z3QxOjRiaILz MW\D[YxtKGO7Y3zlJIFzemW|dDDpckBpfW2jbjDBNlA2QCCvZXzhco9u[SClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzJxTTDwbIF{\SCjdDC1JJVOKGGodHXyJFI1KGi{czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nJIJie2WmIF\BR3Mh[W6jbInzbZM> MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh{OUW5Nkc,Ojh6Mkm1PVI9N2F-
SKOV3 MVHD[YxtKGO7Y3zlJIF{e2G7 M1zBOVIhfU1? NYnueJc6OjRiaILz NIf1UndE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBUU0:YMzDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{KvUUBxcGG|ZTDheEAzKHWPIHHmeIVzKDJ2IHjyd{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oKGKjc3XkJGZCS1NiYX7hcJl{cXN? NHz4RoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEiyPVU6Oid-Mki4Nlk2QTJ:L3G+
SKOV3 NVrDSIJCS2WubDDjfYNt\SCjc4PhfS=> NHz5ZZQzKHWP M17qOVI1KGi{cx?= NF:z[2JE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBUU0:YMzDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiU4XiS|EheGijc3WgZZQhOiC3TTDh[pRmeiB{NDDodpMh[nlicILvdIllcXWvIHnv[Ill\SC|dHHpcolv\yCkYYPl[EBHSUOVIHHuZYx6e2m| NULjV2RQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4Nlk2QTJpPkK4PFI6PTl{PD;hQi=>
MDA-MB-231 MkTrR5l1d3SxeHnjbZR6KGG|c3H5 NH7YVGo4OiCqcoO= NXfxZpZpS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNU45QCEQvF2u NFW3bGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUGwO|QzQSd-MkmxNFc1Ojl:L3G+
PC3 NHzDTGNEgXSxdH;4bYNqfHliYYPzZZk> M3[xTlczKGi{cx?= NITSVndEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFUvOzRizszNMi=> M3z3VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUC3OFI6Lz5{OUGwO|QzQTxxYU6=
T47D MnqzR5l1d3SxeHnjbZR6KGG|c3H5 MYS3NkBpenN? NITSNGdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBVPDeGIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUA3Njl{IN88UU4> M1XzSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUC3OFI6Lz5{OUGwO|QzQTxxYU6=
MCF7 NYrycG0xS3m2b4TvfIlkcXS7IHHzd4F6 M3u1eVczKGi{cx?= NGjYdllEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAyOS5yNTFOwG0v M4\hNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUC3OFI6Lz5{OUGwO|QzQTxxYU6=
TC32 MYLxTHRUKGG|c3H5 MnjBdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFSFM{KgZ4VtdHN? MmH2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
A673 MWfxTHRUKGG|c3H5 MVzxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>? Mn[2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
DAOY NWPF[4NjeUiWUzDhd5NigQ>? Mn\vdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN? Ml;sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Saos-2 NWq4R|MyeUiWUzDhd5NigQ>? M2H2UpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO= NH;XVlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-37 NEnBeWxyUFSVIHHzd4F6 NYLlWmtVeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz MnHxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
RD NHK4bolyUFSVIHHzd4F6 MXPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM> M3PYeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH MUXxTHRUKGG|c3H5 MnnJdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO= NF\xVZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-12 MknzdWhVWyCjc4PhfS=> M2X4c5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?= NH[3TpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
MG 63 (6-TG R) M1GxVZFJXFNiYYPzZZk> NV;ZXoFDeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
NB1643 NVGyRYVieUiWUzDhd5NigQ>? MYTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy| NEO0NlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
OHS-50 MnTqdWhVWyCjc4PhfS=> NX7sdIY6eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=> Mn7EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH NGH1[lVyUFSVIHHzd4F6 NIPOOXlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLWPIJINmdGy| NU\0OY5LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41 Ml65dWhVWyCjc4PhfS=> MXvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>? NX\DS5FsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 MV;xTHRUKGG|c3H5 MXHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDBOlc{KGOnbHzzLS=> M2X1UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh30 MonsdWhVWyCjc4PhfS=> NH;3R3ByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnizNEBk\Wyucx?= MmrSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R) M2fuZZFJXFNiYYPzZZk> M1\JO5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG1IKDZ|IDi2MXRIKFJrIHPlcIx{ MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh30 M1[xR5FJXFNiYYPzZZk> MYPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFMxKGOnbHzz MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
U-2 OS NHrLVZJyUFSVIHHzd4F6 NHftV2JyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBWNTJiT2OgZ4VtdHN? M{HnSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41 MWrxTHRUKGG|c3H5 NVLLc3l5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>? NIH0dWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
RD Mnv4dWhVWyCjc4PhfS=> NEHIS5NyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTTCClZXzsdy=> MliyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2 MWLxTHRUKGG|c3H5 Ml3mdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO= NY\RNJNPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC M1LwSpFJXFNiYYPzZZk> M2LkWZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz NVjXdJVXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1 M{W1UZFJXFNiYYPzZZk> NEfPbYZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=> M2Tx[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5 Ml;DdWhVWyCjc4PhfS=> M1jxRZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?= MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh18 M3nnRZFJXFNiYYPzZZk> MnLPdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN? M3HSOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC NGO3elFyUFSVIHHzd4F6 NWLiNJRleUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?= NYXYZ29LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32 NX3MNWlWeUiWUzDhd5NigQ>? MX7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDUR|MzKGOnbHzz NYLPPWJXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
insect MXfGeY5kfGmxbjDhd5NigQ>? MnniTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCKaYOteIFo\2WmIIC4OYFteGijL4CxNVBidHCqYTDFOVQ2UyCvdYThcpQh\XiycnXzd4VlKGmwIHnud4VkfCClZXzsd{whUUN3MDC9JFAvODFzIN88UU4> MlnXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByM{S2NFcoRjNyMEO0OlA4RC:jPh?=
insect MlXKSpVv[3Srb36gZZN{[Xl? MXjJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKEircz30ZYdo\WRicEi1ZYxxcGFxcEGxNIFteGijIFW1OFJMKG23dHHueEBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzMEBKSzVyIE2gNE4xOjlizszNMi=> MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB|NE[wO{c,OzByM{S2NFc9N2F-
Sf21 MX\GeY5kfGmxbjDhd5NigQ>? M2C5T|EhcHJ? NIDJS|hKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIH\1cIwudGWwZ4ToJG4ufGW{bXnuZYwhUGm|Nj30ZYdo\WRicEGxNIRmdHSjL4LlZ49u[mmwYX70JIh2dWGwIH\1cIwhdGWwZ4ToJJA5PWGucHjhJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDT[lIyKGmwc3XjeEBk\WyuczD1d4lv\yCSSWCyJIF{KHO3YoP0doF1\SCvZXHzeZJm\CCjZoTldkAyKGi{IHL5JGFt\XijNkOzJHRz[WOncj3iZZNm\CCobIXvdoV{[2WwY3WgdI9t[XJuIFnDOVAhRSByLkGyOUDPxE1w NEjqU409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MECzOFYxPyd-M{CwN|Q3ODd:L3G+
MCF7 MWHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M3[yNlczKGi{cx?= MmDFRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPQ1[3JINmdGy|IHjhdoJwemmwZzDQTWs{S0FiRUW0OWshdXW2YX70JIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCwMlIxPiEQvF2u M{j6eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEO0OlA4Lz5|MECzOFYxPzxxYU6=
Sf21 Mo\sSpVv[3Srb36gZZN{[Xl? NFzqOmQyKGi{ MkPXTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsMYxmdme2aDDOMZRmem2rbnHsJGhqezZvdHHn[4VlKHBzMUDi[ZRiN3KnY3;tZolv[W62IHj1cYFvKG[3bHygcIVv\3SqIIC4OYFteGijIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCVZkKxJIlve2WldDDj[YxteyC3c3nu[{BRUVB{IHHzJJN2[nO2cnH0[UBu\WG|dYLl[EBi\nSncjCxJIhzKGK7IFHs[ZhiPjN|IGTyZYNmei2kYYPl[EBndHWxcnXzZ4Vv[2VicH;sZZJqNCCLQ{WwJF0hOC5{M{Sg{txONg>? MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB|NE[wO{c,OzByM{S2NFc9N2F-
T47D M1vEZWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NYnDemNoPzJiaILz Ml3lRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCWNEfEJINmdGy|IHjhdoJwemmwZzDQTVNMS0FiSEGwOFdTKG23dHHueEBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNE4zQDZizszNMi=> NWPpfZRCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN|Q3ODdpPkOwNFM1PjB5PD;hQi=>
PC3 MnHWSpVv[3Srb36gZZN{[Xl? M2jHe|IhcHK| MWfJcohq[mm2aX;uJI9nKFCLM1ugbY4hcHWvYX6gVGM{KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDBT3QheGixc4Doc5J6dGG2aX;uJIF1KFOnckS3N{Bu\WG|dYLl[EBi\nSncjCyJIhzeyCkeTDmcJVwemW|Y3XuZ4Uh[XO|YYmsJGlEPTBiPTCwMlM3PSEQvF2u NIO3N2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MECzOFYxPyd-M{CwN|Q3ODd:L3G+
HT-29 NHfUUItE\WyuIHP5Z4xmKGG|c3H5 M3jwU|AvOTFzIITvJFMhfU1? MnfCNlQhcHK| Mki4R4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gTHQuOjliY3XscJMh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEd{L12gdIhie2ViYYSgNE4yOTFidH:gN{B2VSCjZoTldkAzPCCqcoOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{Bj[XOnZDDmcI94KGO7dH;t[ZRzgQ>? M4\DdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEO0OlA4Lz5|MECzOFYxPzxxYU6=
A2058 NYnm[I5ITnWwY4Tpc44h[XO|YYm= NYm0WppFOSCqch?= M2rwc2lvcGmkaYTpc44hd2ZiVF;SR|IhcW5iaIXtZY4hSTJyNUigZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hWEuEL1HreEBxcG:|cHjvdplt[XSrb36gZZQhW2W{NEezJIFnfGW{IEGgbJIh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nzMEBKSzVyIE2gNE41OTZizszNMi=> MlriQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB|NUmwNFMoRjNyM{W5NFA{RC:jPh?=
A2058 MUDGeY5kfGmxbjDhd5NigQ>? NYLzSoFbOSCqch?= NYT1NpRWUW6qaXLpeIlwdiCxZjDUU3JEOSCrbjDoeY1idiCDMkC1PEBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCVNjDwbI9{eGixconsZZRqd25iYYSgV4VzOjN3L{KzOkBi\nSncjCxJIhzKGK7IGfld5Rmem5iYnzveEBidmGueYPpd{whUUN3MDC9JFAvPTV|IN88UU4> M{jlT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{W5NFA{Lz5|MEO1PVAxOzxxYU6=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT (T308) / p-AKT (S473) / AKT; 

PubMed: 27283525     


Left western blots showing levels of pAkt (T308), pAkt (S473) and total Akt in U87 cells exposed to buparlisib for 72 h. Right densitometric assessment of western blots, showing relative changes in phosphorylation.

p-FOXO3a (S253) / FOXO3a; 

PubMed: 28036259     


Cells were treated with 0.5 μM BKM120 for 24 h and cell lysates were immunoblotted with the indicated antibodies. Actin was used as the loading control.

Nuclear NF-κB p65 / NF-κB p65; 

PubMed: 26673665     


Western blots show BKM120 downregulating pAKT, nuclear NF-κB p65 and total NF-κB p65 in MDR and their parental cells. β-actin was used as a loading control for pAKT, AKT and total NF-κB p65. Lamin B was used as a loading control for nuclear NF-κB p65. 

p-ERK / ERK / LC3; 

PubMed: 27572309     


The indicated cell lines were exposed to different concentrations of BKM120 as indicated for 8 h A. or with 2 μM BKM120 for the indicated times B. The cells were then harvested for preparation of whole-cell protein lysates and subsequent Western blot analysis to detect the given proteins.

p-STAT3 / STAT3 / p-ERK / ERK / p-S6; 

PubMed: 29928341     


Western blot analysis of H460 and H2126 cell lysates using specific antibodies to phosphorylated or total proteins of STAT3, ERK1/2, AKT, S6 or GAPDH (loading control). The cells were treated with increasing concentrations of BKM120 for 24 h.

p-MET / MET; 

PubMed: 29928341     


The expression of phosphorylated or total forms of MET protein was analyzed by western blotting. 

27283525 28036259 26673665 27572309 29928341
Immunofluorescence
FOXO3a; 

PubMed: 28036259     


Cells were cultured on coverslips to approximately 60% confluency and then treated with 1 μM BKM120 for an additional 24 h. Immunofluorescence staining was performed using an anti-FOXO3a antibody and the nuclei were stained with DAPI. Scale bar, 20 μm.

28036259
Growth inhibition assay
Cell viability; 

PubMed: 26673665     


Dose-response curves were used to calculate the IC50 of BKM120 for MCs of MCF-7/A02 cells (upper) and CALDOX cells (lower).

26673665
In vivo BKM120 completely inhibits pAktser473 in A2780 xenograft tumors at doses of 30, 60, or 100 mg/kg, respectively. BKM120 also shows antitumor activity against U87MG glioma model at doses of 30 and 60 mg/kg. [1] BKM120 treatment results in significantly reduced tumor volume and level of circulating human kappa chain at 5 μM/kg/day−1in ARP1 SCID mouse model, with prolonged survival. [2]

Protocol

Kinase Assay:[1]
- Collapse

PI3K biochemical assay (ATP depletion assay):

BKM120 is dissolved in DMSO and directly distributed into a black 384-well plate at 1.25 µL per well. To start the reaction, 25 µL of 10 nM PI3 kinase and 5 µg/mL 1-α-phosphatidylinositol (PI) in assay buffer (10 mM Tris pH 7.5, 5 mM MgCl2, 20 mM NaCl, 1 mM DTT and 0.05% CHAPS) are added into each well followed by 25 µL of 2 µM ATP in assay buffer. The reaction is performed until approx 50% of the ATP is depleted and then stopped by the addition of 25 µL of KinaseGlo solution. The stopped reaction is incubated for 5 minutes and the remaining ATP is then detected via luminescence.
Cell Research:[1]
- Collapse
  • Cell lines: A2780 cells.
  • Concentrations: 0-6.6 μM
  • Incubation Time: 3 days.
  • Method: A2780 cells are cultured in DMEM supplemented with 10% FBS, L-glutamine, sodium pyruvate, and antibiotics. Cells are plated in the same medium at a density of 103 cells per well, 100 μL per well into black-walled-clear-bottom plates and incubated for 3-5 hours. BKM120 supplied in DMSO (20 mM) is diluted. The diluted BKM120 solution (2 μL), is then added to cell medium (500 μL) cell medium (concentration from 0-6.6 μM). Equal volumes of this solution (100 μL) are added to the cells in 96 well plates and incubated at 37 °C for 3 days and developed using Cell Titer Glo. Inhibition of cell proliferation is determined by luminescence read using Trilux.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: U87MG and A2780 xenografts are established in female nu/nu mice.
  • Dosages: ~60 mg/kg.
  • Administration: Dosed orally daily (q.d.).
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 82 mg/mL (199.8 mM)
Ethanol 2 mg/mL (4.87 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 410.39
Formula

C18H21F3N6O2

CAS No. 944396-07-0
Storage powder
in solvent
Synonyms NVP-BKM120
Smiles C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04338399 Recruiting Drug: Buparlisib & Paclitaxel Head and Neck Cancer Adlai Nortye Biopharma Co. Ltd. December 12 2020 Phase 3
NCT02614508 Terminated Drug: Buparlisib|Drug: Ibrutinib|Biological: Ofatumumab Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma Emory University|Novartis January 2016 Phase 1
NCT01613677 Withdrawn Drug: BKM120 Treatment for Metastatic or Locally Advanced Cervical Cancer Novartis Pharmaceuticals|Novartis November 2015 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Buparlisib (BKM120) | Buparlisib (BKM120) supplier | purchase Buparlisib (BKM120) | Buparlisib (BKM120) cost | Buparlisib (BKM120) manufacturer | order Buparlisib (BKM120) | Buparlisib (BKM120) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID